USE IN PREGNANCY
When used in pregnancy during the second and third trimesters, ACE inhibitors can cause injury and even death to the developing fetus. When pregnancy is detected, QUINARETIC should be discontinued as soon as possible. See WARNINGS: Fetal/Neonatal Morbidity and Mortality.
QUINARETIC is a fixed-combination tablet that combines an angiotensin-converting enzyme (ACE) inhibitor, quinapril hydrochloride, and a thiazide diuretic, hydrochlorothiazide.
QUINARETIC is indicated for the treatment of hypertension. This fixed combination is not indicated for the initial therapy of hypertension (see DOSAGE AND ADMINISTRATION).
In using QUINARETIC, consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that quinapril does not have a similar risk (see WARNINGS: Neutropenia/Agranulocytosis).
Angioedema in Black Patients:
Black patients receiving ACE inhibitor monotherapy have been reported to have a higher incidence of angioedema compared to non-blacks. It should also be noted that in controlled clinical trials, ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks.
Media Articles Related to Quinaretic (Quinapril / Hydrochlorothiazide)
Breast cancer treatments could increase risk of developing osteoporosis or hypertension
Source: Health News from Medical News Today [2014.02.28]
Older women who have overcome breast cancer are likely to struggle with heart disease, osteoporosis and hypertension further on in their lives. Whether these conditions occur or not is influenced by the treatment that patients received to fight cancer, their overall weight and their age. Breast cancer survivors therefore should watch their weight and get regular exercise so that they can enjoy a high quality of life. These findings, by lead author Nadia Obi of the University Medical Center Hamburg-Eppendorf, who collaborated with the group of Prof.
10 of 11 new gene signals are likely drug targets for hypertension
Source: Cardiovascular / Cardiology News From Medical News Today [2014.02.24]
A large international study analyzing genes in tens of thousands of individuals has discovered 11 new genetic signals associated with blood pressure levels. Ten of those signals are in or very near genes encoding proteins that appear to be likely targets for drugs already in existence or in development.
Opsumit approved by SwissMedic for pulmonary arterial hypertension
Source: Hypertension News From Medical News Today [2014.02.17]
Actelion Ltd has announced that SwissMedic has approved Opsumit® (macitentan) for PAH patients within Switzerland.Opsumit is indicated for the long-term treatment of pulmonary arterial hypertension (PAH) in patients of WHO Functional Class II to III to reduce morbidity and the risk of mortality.
Air pollution increases risk for hypertension in pregnant women
Source: Hypertension News From Medical News Today [2014.02.14]
Breathing the air outside their homes may be just as toxic to pregnant women - if not more so - as breathing in cigarette smoke, increasing a mom-to-be's risk of developing deadly complications such as preeclampsia, according to findings from a new University of Florida study.
How the body regulates neuro-hormone has implications for hypertension, pain, stress, depression
Source: Anxiety / Stress News From Medical News Today [2014.02.12]
New research has revealed a previously unknown mechanism in the body which regulates a hormone that is crucial for motivation, stress responses and control of blood pressure, pain and appetite. The breakthrough could be used to design drugs to help fight health problems connected with these functions in the future.
Clinical Trials Related to Quinaretic (Quinapril / Hydrochlorothiazide)
Atrial Substrate Modification With Aggressive Blood Pressure Lowering to Prevent AF [Recruiting]
Atrial fibrillation (AF) is a very common arrhythmia causing many symptoms resulting in
numerous hospitalizations. Catheter ablation is a technique that has evolved significantly
to improve symptomatic recurrences, but does not offer a 100% cure rate. We hypothesize
that the use of aggressive BP lowering will reduce the rate of recurrent AF after catheter
ablation for AF. We plan a randomized clinical trial of aggressive BP lowering versus
standard BP control to investigate this. The primary outcome will be time to recurrent AF.
Page last updated: 2014-02-28